Dahlof PowerPoint PPT Presentations

All Time
Show:
Recommended
Sort by:
B'Dahlof Cochair, P'Sever Cochair, N' Poulter Secretary PowerPoint PPT Presentation
B'Dahlof Cochair, P'Sever Cochair, N' Poulter Secretary - B.Dahlof (Co-chair), P.Sever (Co-chair), N. Poulter (Secretary) ... Sever PS, Dahl f B, Poulter N, Wedel H, et al, for the ASCOT Investigators. Lancet. ...
B.Dahlof (Co-chair), P.Sever (Co-chair), N. Poulter (Secretary) ... Sever PS, Dahl f B, Poulter N, Wedel H, et al, for the ASCOT Investigators. Lancet. ...
| PowerPoint PPT presentation | free to view
Migraine in adults: 1-year prevalence PowerPoint PPT Presentation
Migraine in adults: 1-year prevalence - Rasmussen. Bank. Launer. Hagen. Dahlof. Steiner. Kryst. Schwartz ... Rasmussen. Schwartz. Lavados. Wiehe. 86.5. Lyngberg. Mean: 48.6. Median: 38.3. Tension-type ...
Rasmussen. Bank. Launer. Hagen. Dahlof. Steiner. Kryst. Schwartz ... Rasmussen. Schwartz. Lavados. Wiehe. 86.5. Lyngberg. Mean: 48.6. Median: 38.3. Tension-type ...
| PowerPoint PPT presentation | free to download
Chronic therapy of cardiovascular disease PowerPoint PPT Presentation
Chronic therapy of cardiovascular disease - Atenolol vs Losartan. 9193 patients. Age 55-80 years. Previously treated or untreated hypertension ... Atenolol 80.9 mm Hg. Losartan 81.3 mm Hg. B Dahlof et al. ...
Atenolol vs Losartan. 9193 patients. Age 55-80 years. Previously treated or untreated hypertension ... Atenolol 80.9 mm Hg. Losartan 81.3 mm Hg. B Dahlof et al. ...
| PowerPoint PPT presentation | free to view
Losartan Intervention For Endpoint Reduction in Hypertension Study PowerPoint PPT Presentation
Losartan Intervention For Endpoint Reduction in Hypertension Study - Double-blind, randomized trial to compare the effects of losartan and ... angina pectoris. heart failure. coronary or peripheral revascularization procedures ...
Double-blind, randomized trial to compare the effects of losartan and ... angina pectoris. heart failure. coronary or peripheral revascularization procedures ...
| PowerPoint PPT presentation | free to view
OPTIMAAL: Does the dose make the medicine? PowerPoint PPT Presentation
OPTIMAAL: Does the dose make the medicine? - Title: Coaated stents: a new era Subject: theheart.org show Author: Conceptis Technologies Last modified by: Laurent Castellucci Created Date
Title: Coaated stents: a new era Subject: theheart.org show Author: Conceptis Technologies Last modified by: Laurent Castellucci Created Date
| PowerPoint PPT presentation | free to download
Chronic therapy of cardiovascular disease PowerPoint PPT Presentation
Chronic therapy of cardiovascular disease - Title: Coaated stents: a new era Subject: theheart.org show Author: Conceptis Technologies Last modified by: sys admin Created Date: 2/9/2001 4:03:24 PM
Title: Coaated stents: a new era Subject: theheart.org show Author: Conceptis Technologies Last modified by: sys admin Created Date: 2/9/2001 4:03:24 PM
| PowerPoint PPT presentation | free to download
Hypertension and The Heart PowerPoint PPT Presentation
Hypertension and The Heart - FDR's Final Picture (April 11, 1945) FDR's BP as recorded April 1944 at Bethesda Naval Hospital ... Diffuse, Dilatory. Fibrotic (elastin breakdown, collagen increase) ...
FDR's Final Picture (April 11, 1945) FDR's BP as recorded April 1944 at Bethesda Naval Hospital ... Diffuse, Dilatory. Fibrotic (elastin breakdown, collagen increase) ...
| PowerPoint PPT presentation | free to view
Role of Fenofibrate in Diabetic Dyslipidemia PowerPoint PPT Presentation
Role of Fenofibrate in Diabetic Dyslipidemia - Role of Fenofibrate in Diabetic Dyslipidemia Diabetic Dyslipidaemia Occurs in type 2 diabetes mellitus High levels of triglycerides Low levels of HDL-C LDL-C not ...
Role of Fenofibrate in Diabetic Dyslipidemia Diabetic Dyslipidaemia Occurs in type 2 diabetes mellitus High levels of triglycerides Low levels of HDL-C LDL-C not ...
| PowerPoint PPT presentation | free to download
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hyperten PowerPoint PPT Presentation
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hyperten - Beta blockers; alpha blockers; clonidine; (loop diuretics). 14 Days ... Includes patients receiving beta blockers, alpha blockers, clonidine, loop diuretics. ...
Beta blockers; alpha blockers; clonidine; (loop diuretics). 14 Days ... Includes patients receiving beta blockers, alpha blockers, clonidine, loop diuretics. ...
| PowerPoint PPT presentation | free to view
Implications of ASCOT Results for ALLHAT Conclusions PowerPoint PPT Presentation
Implications of ASCOT Results for ALLHAT Conclusions - ASCOT was not a comparison of initial treatment with newer drugs versus thiazide ... Even for total mortality, concomitant interventions can introduce confounding, ...
ASCOT was not a comparison of initial treatment with newer drugs versus thiazide ... Even for total mortality, concomitant interventions can introduce confounding, ...
| PowerPoint PPT presentation | free to view
Blood Pressure Lowering Treatment Trialists Collaboration Second cycle of overview analyses PowerPoint PPT Presentation
Blood Pressure Lowering Treatment Trialists Collaboration Second cycle of overview analyses - Established in 1995 by the principal investigators of ongoing ... diuretic/beta-blocker. 141. 758. UKPDS-HDS. 6031. 47430. Total. 897. 4418. STOP-2. 698. 10985 ...
Established in 1995 by the principal investigators of ongoing ... diuretic/beta-blocker. 141. 758. UKPDS-HDS. 6031. 47430. Total. 897. 4418. STOP-2. 698. 10985 ...
| PowerPoint PPT presentation | free to view
Pharmacologic Strategy for Treating Patients with Diabetes and Vascular Disease: A Polypharmacy Appr PowerPoint PPT Presentation
Pharmacologic Strategy for Treating Patients with Diabetes and Vascular Disease: A Polypharmacy Appr - Useful in combo RX. Improves Insulin resistance at the hepatic level. TZDs Improve CV Risks ... CARDS, Collaborative Atorvastatin Diabetes Study. Colhoun HM, ...
Useful in combo RX. Improves Insulin resistance at the hepatic level. TZDs Improve CV Risks ... CARDS, Collaborative Atorvastatin Diabetes Study. Colhoun HM, ...
| PowerPoint PPT presentation | free to view
Marcelo E. Bigal, M.D.; Ph.D. PowerPoint PPT Presentation
Marcelo E. Bigal, M.D.; Ph.D. - ... migraine on the individual, family and society. Is migraine ... To estimate patterns of diagnosis and treatment for migraine, as well as barriers for care ...
... migraine on the individual, family and society. Is migraine ... To estimate patterns of diagnosis and treatment for migraine, as well as barriers for care ...
| PowerPoint PPT presentation | free to download
Case Discussion PowerPoint PPT Presentation
Case Discussion - HCTZ stopped by primary MD, atenolol added at 50 mg daily, increased to 100 mg ... Atenolol 50 mg. Losartan 50 mg HCTZ 12.5 mg. Losartan 100 mg HCTZ 12.5 mg ...
HCTZ stopped by primary MD, atenolol added at 50 mg daily, increased to 100 mg ... Atenolol 50 mg. Losartan 50 mg HCTZ 12.5 mg. Losartan 100 mg HCTZ 12.5 mg ...
| PowerPoint PPT presentation | free to view
Epinephrine Metered Dose Inhaler: An Essential OTC Asthma Medicine PowerPoint PPT Presentation
Epinephrine Metered Dose Inhaler: An Essential OTC Asthma Medicine - How many people with asthma do not have ready access to prescription medication ... 3. IRI FDMX YTD 11/6/05 augmented with WalMart estimated at 27% of FDMW. 33 ...
How many people with asthma do not have ready access to prescription medication ... 3. IRI FDMX YTD 11/6/05 augmented with WalMart estimated at 27% of FDMW. 33 ...
| PowerPoint PPT presentation | free to view
Sesin Bibliogrfica 2669 Betabloqueantes en el tratamiento de la hipertensin: a quin y cundo Ong HT' PowerPoint PPT Presentation
Sesin Bibliogrfica 2669 Betabloqueantes en el tratamiento de la hipertensin: a quin y cundo Ong HT' - Pacientes hipertensos, de ambos sexos, en tratamiento con betabloqueantes e ... Por encima de los 60 a os de edad no est justificado su uso para tratar la ...
Pacientes hipertensos, de ambos sexos, en tratamiento con betabloqueantes e ... Por encima de los 60 a os de edad no est justificado su uso para tratar la ...
| PowerPoint PPT presentation | free to view
New Era Of Comparative Effectiveness Research PowerPoint PPT Presentation
New Era Of Comparative Effectiveness Research - www.healthaffairs.org
www.healthaffairs.org
| PowerPoint PPT presentation | free to view
S??????? ?e?ape?t??? p??s????s? ?p??tas?? ?????? PowerPoint PPT Presentation
S??????? ?e?ape?t??? p??s????s? ?p??tas?? ?????? - Title: PowerPoint Presentation Author: ANDREAS PITTARAS 6932416145 Last modified by: Nickos Created Date: 1/1/1601 12:00:00 AM Document presentation format
Title: PowerPoint Presentation Author: ANDREAS PITTARAS 6932416145 Last modified by: Nickos Created Date: 1/1/1601 12:00:00 AM Document presentation format
| PowerPoint PPT presentation | free to view
St PowerPoint PPT Presentation
St - Age (men 55 yr; women 65 yr) Family history of premature CVD ... TROPHY: Kaplan-Meier Curves. of New Onset Clinical Hypertension. LIFESTYLE MODIFICATIONS ...
Age (men 55 yr; women 65 yr) Family history of premature CVD ... TROPHY: Kaplan-Meier Curves. of New Onset Clinical Hypertension. LIFESTYLE MODIFICATIONS ...
| PowerPoint PPT presentation | free to view
Improving Blood Pressure Treatment in the Community: Implications of the JNC7 Recommendations and AL PowerPoint PPT Presentation
Improving Blood Pressure Treatment in the Community: Implications of the JNC7 Recommendations and AL - Improving Blood Pressure Treatment in the Community: Implications of the JNC7 Recommendations and AL
Improving Blood Pressure Treatment in the Community: Implications of the JNC7 Recommendations and AL
| PowerPoint PPT presentation | free to view
Stroke Treatment Advances PowerPoint PPT Presentation
Stroke Treatment Advances - Stroke Treatment Advances Franz Chaves Sell Neurology, Hospital Cl nica B blica, San Jos , Costa Rica Academia Nacional de Medicina SIECV
Stroke Treatment Advances Franz Chaves Sell Neurology, Hospital Cl nica B blica, San Jos , Costa Rica Academia Nacional de Medicina SIECV
| PowerPoint PPT presentation | free to download
Anne E. ODuffy, MD PowerPoint PPT Presentation
Anne E. ODuffy, MD - SAPPHIRE: Stenting and Angioplasty with Protection in Patients at High Risk for ... 723 pts, symptomatic 50%, asymptomatic 80% plus one co-morbidity (CHF, recent ...
SAPPHIRE: Stenting and Angioplasty with Protection in Patients at High Risk for ... 723 pts, symptomatic 50%, asymptomatic 80% plus one co-morbidity (CHF, recent ...
| PowerPoint PPT presentation | free to view
Lecture dun essai dintervention sur la morbimortalit cardiovasculaire de lhypertendu' PowerPoint PPT Presentation
Lecture dun essai dintervention sur la morbimortalit cardiovasculaire de lhypertendu' - Captopril and conventional treatment did not differ in preventing CV ... mais il ne doit pas masquer l'insuffisance de chaque crit re pris individuellement. ...
Captopril and conventional treatment did not differ in preventing CV ... mais il ne doit pas masquer l'insuffisance de chaque crit re pris individuellement. ...
| PowerPoint PPT presentation | free to view
Heart Failure PowerPoint PPT Presentation
Heart Failure - Heart Failure Susan Schayes, MD, MPH Program Director Emory Family Medicine Residency Program Adapted from Dr. Joel Felner and Dr. Eddie Needham Summary Points ...
Heart Failure Susan Schayes, MD, MPH Program Director Emory Family Medicine Residency Program Adapted from Dr. Joel Felner and Dr. Eddie Needham Summary Points ...
| PowerPoint PPT presentation | free to download
Preventing Stroke in Primary Care Clinical recommendations from the Alberta Provincial Stroke Strate PowerPoint PPT Presentation
Preventing Stroke in Primary Care Clinical recommendations from the Alberta Provincial Stroke Strate - Kaplan-Meier stroke-free survival curves. ER DP. ASA/ER DP. ASA. Placebo ... 102 cm for men, 88 cm for women ? Insulin Resistance (metabolic syndrome) ...
Kaplan-Meier stroke-free survival curves. ER DP. ASA/ER DP. ASA. Placebo ... 102 cm for men, 88 cm for women ? Insulin Resistance (metabolic syndrome) ...
| PowerPoint PPT presentation | free to view
Diabetes subgroup analyses PowerPoint PPT Presentation
Diabetes subgroup analyses - diuretic/beta-blocker. 17433. 8323. ACE vs. CA. 125,314. 33,395. All ... diuretic/beta-blocker. 12339. 5019. ARB vs. other. 18383. 3599. More vs. less intensive ...
diuretic/beta-blocker. 17433. 8323. ACE vs. CA. 125,314. 33,395. All ... diuretic/beta-blocker. 12339. 5019. ARB vs. other. 18383. 3599. More vs. less intensive ...
| PowerPoint PPT presentation | free to view
Hypertension in the Elderly and Additional Data from the ALLHAT Study PowerPoint PPT Presentation
Hypertension in the Elderly and Additional Data from the ALLHAT Study - Hypertension in the Elderly and Additional Data from the ALLHAT Study William C. Cushman, MD, FACP Professor, Preventive Medicine and Medicine University of Tennessee
Hypertension in the Elderly and Additional Data from the ALLHAT Study William C. Cushman, MD, FACP Professor, Preventive Medicine and Medicine University of Tennessee
| PowerPoint PPT presentation | free to view
Tout sur lAVC en 3 heures PowerPoint PPT Presentation
Tout sur lAVC en 3 heures - L'aspirine a t valu e dans l'infarctus c r bral aigu ( 48 h) dans de larges tudes randomis es et ... des patients avec un infarctus c r bral aigu (Cat gorie I, Niveau A) ...
L'aspirine a t valu e dans l'infarctus c r bral aigu ( 48 h) dans de larges tudes randomis es et ... des patients avec un infarctus c r bral aigu (Cat gorie I, Niveau A) ...
| PowerPoint PPT presentation | free to view
Stratgie efficace et fiable de rglage posologique avec COZAAR, HYZAAR et HYZAARDS pour la matrise de PowerPoint PPT Presentation
Stratgie efficace et fiable de rglage posologique avec COZAAR, HYZAAR et HYZAARDS pour la matrise de - Seulement 36 % des patients ont d avoir un r glage posologique HYZAAR et 19 % des patients ont eu besoin d'un r glage posologique additionnel HYZAAR DS. ...
Seulement 36 % des patients ont d avoir un r glage posologique HYZAAR et 19 % des patients ont eu besoin d'un r glage posologique additionnel HYZAAR DS. ...
| PowerPoint PPT presentation | free to view
Presentacin de PowerPoint PowerPoint PPT Presentation
Presentacin de PowerPoint - Colesterol, mg/dl 232 236. Glucosa, mg/dl 108 111. B Dahlof et al. Lancet 2002;359:995-1003 ... 50 mg. ATENOLOL. LOSARTAN. DOSIS. LIFE: Presi n Arterial y ...
Colesterol, mg/dl 232 236. Glucosa, mg/dl 108 111. B Dahlof et al. Lancet 2002;359:995-1003 ... 50 mg. ATENOLOL. LOSARTAN. DOSIS. LIFE: Presi n Arterial y ...
| PowerPoint PPT presentation | free to view


Home About Us Terms and Conditions Privacy Policy Contact Us
Copyright 2024 CrystalGraphics, Inc. — All rights Reserved. PowerShow.com is a trademark of CrystalGraphics, Inc.
dahlof — Search results on PowerShow.com